The Therapeutic Value of Erythropoietin in Preventing the Negative Effects of Methotrexate on the Stomach
Main Article Content
Abstract
Aim: The current study aimed to evaluate any potential protective effects of erythropoietin (Epo) and
identify potential histological adverse changes in the stomach caused by methotrexate (MTX) therapy.
Materials and Methods: There were 60 mature albino rats (about 250 g) in the study. Three equal groups
of 20 rats each were created out of the animals. For 9 weeks, the animals in the first control group received
intraperitoneal injections of normal saline twice a week at a dose of 0.5 mg/kg. For duration of 9 weeks,
animals in Group 2 received intraperitoneal injections of MTX hydrate twice a week at a dose of 0.5 mg/kg.
The animals in Group 3 were given intraperitoneal injections of MTX hydrate at a dosage of 0.5 mg/kg twice
a week for 9 weeks, along with subcutaneous injections of 100 IU/kg recombinant human Epo once a week.
Results and Discussion: The stomach tissue’s morphological and histological alterations were evaluated. The
contents of glutathione peroxidase, superoxide dismutase, glutathione, and IL-2 and IL-6 (interleukin 6) in the
serum sample were then determined. Epo demonstrated pronounced antioxidant properties and mitigated MTX’s
deleterious effects on stomach histology. Conclusion: Our findings point to the need for more investigation into
the potential use of Epo as a medication to shield patients from MTX’s side effects.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.